Last updated: May 29, 2026

Application No. 17/913,899

CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

Non-Final OA

Filed

Sep 23, 2022

Priority

Mar 31, 2020 — JP 2020-062881 +2 more

Examiner

NICKOL, GARY B

Art Unit

1643

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Chugai Seiyaku Kabushiki Kaisha

OA Round

1 (Non-Final)

This examiner grants 44% of cases after interview

— +26.4% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 57 resolved cases, 2023–2026

Examiner Intelligence

NICKOL, GARY B View full profile →

Grants 44% of resolved cases

Career Allowance Rate

25 granted / 57 resolved

-16.1% vs TC avg

Strong +26% interview lift

Without

With

+26.4%

Interview Lift

resolved cases with interview

Typical timeline

3y 9m

Avg Prosecution

36 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

2.5%

-37.5% vs TC avg

§103

31.1%

-8.9% vs TC avg

§102

14.9%

-25.1% vs TC avg

§112

33.5%

-6.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Prosecution Timeline

Sep 23, 2022

Application Filed

Nov 17, 2025

Request for Continued Examination

Nov 18, 2025

Response after Non-Final Action

Jan 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/621,711

Patent 12605425

TNF MUTEINS AND USES THEREOF

4y 4m to grant Granted Apr 21, 2026

17/638,453

Patent 12599620

METHOD FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME USING AN INHIBITORY OR CYTOTOXIC AGENT AGAINST PLASMA CELLS

4y 1m to grant Granted Apr 14, 2026

17/051,860

Patent 12577286

T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR

5y 4m to grant Granted Mar 17, 2026

17/442,072

Patent 12534538

ANTI-HER2 BINDING MOLECULES

4y 4m to grant Granted Jan 27, 2026

17/759,854

Patent 12492251

HUMAN BLOOD-BRAIN BARRIER TARGETING ANTIBODIES

3y 4m to grant Granted Dec 09, 2025

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

44%

Grant Probability

70%

With Interview (+26.4%)

3y 9m (~1m remaining)

Median Time to Grant

Low

PTA Risk

Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.